Myriad reports positive results for Alzheimer’s drug
In the phase II trial, many patients with Alzheimer's disease got no worse over two full years, and in some cases, patients treated with Flurizan appear to have
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.